Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimebon + Donepezil Extension in AD
NCT00704782Phase 2Terminated
- Sponsor
- Medivation
- Start
- Apr 2008
- Primary completion
- Aug 2010
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of latrepirdine in Alzheimer's disease (AD), sponsored by Medivation. Primary endpoint: Safety of Dimebon in combination with donepezil. Started Apr 2008; status: terminated.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00704782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704782.